CBIO — CRESCENT BIOPHARMA, INC.

Nasdaq · Health Care · Pharmaceuticals · CIK 1253689 ·
Last close
$14.47
Market Cap
$534.81M
52W High
$22.52
52W Low
$13.99
ADV30
448,715
Next earnings
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 1,039,000 -24,729,000 -23,283,000 199,130,000 189,163,000 15,283,000
Dec 2025 10,844,000 -91,492,000 -92,397,000 240,293,000 213,192,000 37,281,000
Sep 2025 0 -25,885,000 -24,607,000 138,269,000 133,265,000 21,628,000
Jun 2025 0 -21,030,000 -21,790,000 157,433,000 152,645,000 18,179,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-69,618,000
Investing CF
$-81,066,000
Financing CF
$317,525,000
CapEx
$-80,926,000
Dividends Paid
Buybacks
$0
EPS Diluted TTM
$-10.91
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-195,092,000
Inventory
Receivables
$0
ST Investments
EBIT TTM
$-159,004,000
Pretax Income TTM
$-160,077,000
Interest Exp TTM
$1,073,000
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$11,883,000
EBITDA
Free Cash Flow
Enterprise Value
$315,480,416
Total Cash
$189,163,008
Total Debt
$1,543,000
Shares Out
36,959,831
Trailing EPS
$-0.14
Book Value
$5.41
ROE
ROA
Div Yield

Annual Trend (SEC EDGAR, last 2y)

Revenues vs Net Income (last 2y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 10,844,000 -152,632,000 -153,942,000 240,293,000 37,281,000 -71,532,000
Dec 2024 35,617,000 51,096,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-2.98

Peers — same industry

TickerNameMarket CapLastDaily %
ARVN ARVINAS, INC. $518.11M $8.03
ALT Altimmune, Inc. $552.31M $2.84
MPLT MapLight Therapeutics, Inc. $554.89M $13.02
RLMD RELMADA THERAPEUTICS, INC. $557.48M $5.31
VSTM Verastem, Inc. $509.67M $5.80

News headlines (Yahoo Finance, 1h cache)

Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-07-30 11:35 · Yahoo
Crescent Biopharma Announces Grants of Inducement Awards
2026-07-23 20:15 · Yahoo
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2026-07-16 20:01 · Yahoo
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
2026-07-15 01:45 · Yahoo
Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
2026-07-14 20:01 · Yahoo
Crescent Biopharma to Present at June Investor Conferences
2026-06-02 20:15 · Yahoo
Crescent Biopharma to Present at May Investor Conferences
2026-05-06 11:30 · Yahoo
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-04-29 20:15 · Yahoo
Crescent Biopharma: Q4 Earnings Snapshot
2026-02-26 13:05 · Yahoo
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
2026-02-26 12:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.